Skip to Content

BiovaxID Approval Status

FDA Approved: No
Brand name: BiovaxID
Company: Biovest International, Inc.
Treatment for: Non-Hodgkin's Lymphoma

BiovaxID is a personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin’s lymphoma.

Development Status and FDA Approval Process for BiovaxID

DateArticle
Jun 22, 2010Biovest Announces Mantle Cell Lymphoma as Next Target Indication for Personalized Cancer Vaccine
Jun  5, 2007Biovest to File for Accelerated Conditional Approval of BiovaxID
Feb 22, 2006Biovest International Submits Amendment Request to FDA for Use of Molecular Remission Data in the Ongoing Pivotal Phase 3 Study to Support Accelerated, Conditional Approval of BiovaxID, a Personalized Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide